This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiovascular disease	Serotonin (5-HT ₃) receptor (HTR _{3A})	<p><i>In vitro</i> and rodent studies suggest that a series of pyrroloquinoxaline analogs could help treat cardiovascular conditions. In cardiac tissue preparations from guinea pigs, four of the analogs had cardiomodulator effects via HTR_{3A}. Also in mice, the analogs had poor blood brain barrier permeability, suggesting the compounds acted peripherally. Next steps could include optimizing the analogs for testing in additional animal models of cardiac disorders.</p> <p>At least 11 companies have HTR_{3A} antagonists or partial agonists in development or marketed for a variety of indications.</p> <p>SciBX 2(22); doi:10.1038/scibx.2009.907 Published online June 4, 2009</p>	Patent and licensing status unavailable	<p>Morelli, E. <i>et al. J. Med. Chem.</i>; published online May 8, 2009; doi:10.1021/jm900018b</p> <p>Contact: Giuseppe Campiani, Siena University, Siena, Italy e-mail: campiani@unisi.it</p>